Abate M et al. A novel microbiome signature in gastric cancer: A two independent cohort retrospective analysis. Ann Surg 2022;276(4):605-15. Abstract
Ajani JA et al. Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma. ESMO 2023;Abstract LBA82.
Al-Batran S-E et al. Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study. ESMO 2023;Abstract LBA73.
Chakrabarti S et al. Anti-HER2 therapy following ctDNA-identified ERBB2 amplification for patients with advanced gastric cancer: Exploration of real-world outcomes and resistance mechanisms. ESMO GI 2023;Abstract PD-9.
Cytryn SL et al. Cell free DNA (cfDNA) assessment of esophagogastric (EG) cancer using MSK-ACCESS. Gastrointestinal Cancers Symposium 2024;Abstract 406.
Cytryn SL et al. Cell free DNA (cfDNA) assessment of esophagogastric (EG) cancer using MSK-ACCESS. ASCO 2023;Abstract 4036.
Diplas BH et al. Clinical importance of clonal hematopoiesis in metastatic gastrointestinal tract cancers. JAMA Netw Open 2023;6(2):e2254221. Abstract
Epistola R et al. Role of PD-1 inhibitors in the treatment of esophagogastric adenocarcinoma: Patient selection and reported outcomes. Cancer Manag Res 2023;15:265-75. Abstract
Hsu C-H et al. SKYSCRAPER-08: A phase III, randomized, double-blind, placebo-controlled study of first-line (1L) tiragolumab (tira) + atezolizumab (atezo) and chemotherapy (CT) in patients (pts) with esophageal squamous cell carcinoma (ESCC). Gastrointestinal Cancers Symposium 2024;Abstract 245.
Hubner R et al. Randomized, global, phase III study of tislelizumab (TIS) + chemotherapy (chemo) vs placebo (PBO) + chemo as first-line (1L) treatment for advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 update. ESMO 2023;Abstract 1514P.
Janjigian YY et al. Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study. Gastrointestinal Cancers Symposium 2024;Abstract LBA246.
Janjigian YY et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: Interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet 2023;402(10418):2197-208. Abstract
Kelly R et al. Adjuvant nivolumab vs placebo in resected esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: First report of comprehensive biomarker analyses from CheckMate 577. ESMO GI 2023;Abstract O-7.
Klempner SJ et al. A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab + chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA). ASCO 2023;Abstract 4027.
Klempner SJ et al. ILUSTRO: Phase II multicohort trial of zolbetuximab in patients with advanced or metastatic claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma. Clin Cancer Res 2023;29(19):3882-91. Abstract
Lee K et al. Zanidatamab (zani) plus chemotherapy (chemo) and tislelizumab (tis) as first-line (1l) therapy for patients (pts) with advanced HER2-positive (+) gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a phase Ib/II study. ESMO 2023;Abstract 1518P.
Lei M et al. Nivolumab (NIVO) plus (+) chemotherapy (chemo) or ipilimumab (IPI) vs chemo as 1L treatment for advanced esophageal squamous cell carcinoma (ESCC): First comprehensive biomarker analyses from CheckMate 648. Gastrointestinal Cancers Symposium 2024;Abstract 252.
Li Y et al. Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial. Gastrointestinal Cancers Symposium 2024;Abstract LBA244.
Lordick F et al. Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab + CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma. ESMO 2023;Abstract LBA81.
Lorenzen S et al. Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: The phase II/III RAMIRIS study (AIO-STO-0415). BMC Cancer 2023;23(1):561. Abstract
Lumish MA et al. Clinical and molecular characteristics of early-onset vs average-onset esophagogastric cancer. J Nat Cancer Inst 2024;116(2):299-308. Abstract
Magahis PT et al. Impact of helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors. J Immunother Cancer 2023;11(10):e007699. Abstract
Rha SY et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): A multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2023;24(11):1181-95. Abstract
Saeed A et al. SWOG S2303: Randomized phase II/III trial of 2nd line nivolumab + paclitaxel + ramucirumab versus paclitaxel + ramucirumab in patients with PD-L1 CPS ≥ 1 advanced gastric and esophageal adenocarcinoma (PARAMUNE). Gastrointestinal Cancers Symposium 2024;Abstract TPS430.
Shah MA et al. First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced esophageal cancer: 5-year outcomes from the phase 3 KEYNOTE-590 study. Gastrointestinal Cancers Symposium 2024;Abstract 250.
Shah MA et al. Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO Guideline. J Clin Oncol 2023;41(7):1470-91. Abstract
Shitara K et al. Management of nausea and vomiting (N/V) following first-line (1L) zolbetuximab + chemotherapy treatment in claudin-18.2 (CLDN18.2)+, HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Analysis from the phase 3 SPOTLIGHT and GLOW studies. Gastrointestinal Cancers Symposium 2024;Abstract 372.
Shitara K et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer KEYNOTE-585): An interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol 2024;25(2):212-24. Abstract
Shitara K et al. Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year (yr) follow-up of CheckMate 649. Gastrointestinal Cancers Symposium 2024;Abstract 306.
Shitara K et al. Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: Exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial. J Immunother Cancer 2023;11(6):e006920. Abstract
Shitara K et al. Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS). J Cancer Res Clin Oncol 2023;149(11):9361-74. Abstract
Tehfe M et al. Phase II dose optimization results from MOUNTAINEER-02: A study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal cancer (GEC). ESMO 2023;Abstract 1523P.
Van Cutsem E et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): Primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol 2023;24(7):744-56. Abstract
Wang Y et al. First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors. ASCO 2023;Abstract 3016.
Xu R-H et al. Tislelizumab (TIS) plus chemotherapy (chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study. ESMO 2023;Abstract LBA80.
Yamaguchi K et al. Trastuzumab deruxtecan in anti-human epidermal growth factor receptor 2 treatment-naive patients with human epidermal growth factor receptor 2-low gastric or gastroesophageal junction adenocarcinoma: Exploratory cohort results in a Phase II trial. J Clin Oncol 2023;41(4):816-25. Abstract
Yang J, Janjigian YY. Immune checkpoint blockade and targeted therapies in esophageal cancer. Thorac Surg Clin 2022;32(4):467-78. Abstract